Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Quantum Genomics    ALQGC   FR0011648971

QUANTUM GENOMICS

(ALQGC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners

11/02/2020 | 12:00pm EST

PARIS and NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the end of its financing agreement with Negma Group Ltd/Park Partners.

Signed last March 2020 at the beginning of the COVID-19 pandemic, this financing, which includes a loan not exceeding €8 million and the issue of share subscription warrants, was renewable twice. The Company has already confirmed that this financing will not be renewed and will end at the end of the first instalment of €8 million.

To date, Quantum Genomics has redeemed the totality of this financing of €8 million and has issued 3,243,213 ordinary shares. The financial debt contracted with Negma Group Ltd has now been fully repaid. Negma Group Ltd has sold its last shares on the market.

Main terms of this financing agreement were detailed in a press release issued March 26, 2020.

Main figures of financing agreement with Negma Group Ltd

Amount redeemed: € 8 million in four instalments of € 2 million

Ordinary shares issued to date: 3,243,213

Remaining debt to be reimbursed by shares emission: € 0

Number of ordinary shares to be sold on the market by Negma Group Ltd: 0

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF)

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contacts

Quantum Genomics 
Jean-Philippe Milon
CEO
jean-philippe.milon@quantum-genomics.com
Benoît Gueugnon
CFO
benoit.gueugnon@quantum-genomics.com
So Bang (Europe)  
Nathalie Boumendil
Financial Communications
+33 (0)6 85 82 41 95 | nathalie@so-bang.fr
Samuel Beaupain
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | samuel@so-bang.fr
LifeSci (USA) 
Dan Ferry
Financial Communications
+1 (617) 430-7576 | Daniel@lifesciadvisors.com
Mike Tattory
Media Relations and Scientific Communications
+1 (609) 802-6265 | mtattory@lifescicomms.com 

Primary Logo


© GlobeNewswire 2020
All news about QUANTUM GENOMICS
01/19QUANTUM GENOMICS : Launch of the REFRESH Trial Pivotal Phase III Study in Diffic..
AQ
01/18Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-tre..
GL
01/18QUANTUM GENOMICS : Kicks Off Phase III REFRESH Study for Hypertension Drug
MT
01/18QUANTUM GENOMICS : Quantum Genomics Launches Phase III Pivotal REFRESH Study in ..
AN
01/13QUANTUM GENOMICS : - Letter to Shareholders
AQ
2020QUANTUM GENOMICS : signs strategic contract with Delpharm
AQ
2020QUANTUM GENOMICS : Quantum Genomics Signs a Strategic Contract with Delpharm
AN
2020Quantum Genomics Signs a Strategic Contract with Delpharm
GL
2020QUANTUM GENOMICS : Signs Deal To Develop, Commercialize Hypertension Drug In Gre..
MT
2020QUANTUM GENOMICS : Quantum Genomics Enters into Exclusive Licensing and Collabor..
AN
More news
Financials
Sales 2020 4,00 M 4,86 M 4,86 M
Net income 2020 -9,99 M -12,2 M -12,2 M
Net cash 2020 8,61 M 10,5 M 10,5 M
P/E ratio 2020 -10,2x
Yield 2020 -
Capitalization 129 M 156 M 157 M
EV / Sales 2020 30,1x
EV / Sales 2021 18,9x
Nbr of Employees 11
Free-Float 95,9%
Chart QUANTUM GENOMICS
Duration : Period :
Quantum Genomics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUANTUM GENOMICS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 16,80 €
Last Close Price 4,83 €
Spread / Highest target 248%
Spread / Average Target 248%
Spread / Lowest Target 248%
EPS Revisions
Managers and Directors
NameTitle
Jean-Philippe Milon Chief Executive Officer & Director
Lionel Ségard Chairman
Benoît Gueugnon Chief Financial Officer
Fabrice Balavoine Vice President-Research & Development
Bruno Besse Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
QUANTUM GENOMICS-1.43%156
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
IQVIA HOLDINGS INC.6.35%36 531
SEAGEN INC.8.94%34 515